Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03503630
Other study ID # BIO-2017-0422
Secondary ID MS100070_0021 IS
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date July 20, 2018
Est. completion date July 2, 2024

Study information

Verified date January 2024
Source American University of Beirut Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.


Description:

The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer. COMPOUND 2055269 has demonstrated meaningful clinical activity across various tumor types and treatment settings. No clinical trial is conducted over COMPOUND 2055269 in locally-advanced rectal adenocarcinoma.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 44
Est. completion date July 2, 2024
Est. primary completion date March 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients aged =18 years. 2. Locally-advanced rectal cancer (cT2 N1-3, cT3 N0-3, evidence of extramural vascular or mesorectal fascia involvement). 3. <12 cm from anal verge. 4. Histologically proven rectal adenocarcinoma. 5. ECOG performance score = 1. 6. Have adequate organ function by meeting the following: - Absolute neutrophil count (ANC) = 1.5 × 109/L; - Platelet count = 100 × 109/L; - Hemoglobin = 9 g/dL; - Total bilirubin level = 1.5 × the upper limit of normal (ULN) range; - AST and ALT levels = 2.5 × ULN or AST and ALT levels = 5 x ULN (for subjects with documented metastatic disease to the liver); - Estimated creatinine clearance = 30 mL/min according to the Cockcroft- Gault formula (or local institutional standard method). 7. Negative serum or urine pregnancy test at screening for women of childbearing potential. 8. Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last COMPOUND 2055269 treatment administration if the risk of conception exists. Exclusion Criteria: 1. Distant metastasis (M1). 2. Patients with T2 N0 or T4. 3. Recurrent rectal cancer. 4. Symptoms or history of peripheral neuropathy. 5. Prior radiotherapy or chemotherapy. 6. Current use of immunosuppressive medication, except for the following: - Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intraarticular injection); - Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; - Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). 7. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible. 8. Vaccination within 4 weeks of the first dose of COMPOUND 2055269 and while on trials is prohibited except for administration of inactivated vaccines. 9. Active infection requiring systemic therapy. 10. Known history of testing positive for the human immunodeficiency virus or known acquired immunodeficiency syndrome. 11. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive). 12. Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade = 3). 13. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. 14. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade = 2, or other Grade = 2 not constituting a safety risk based on investigator's judgment are acceptable. 15. Prior organ transplantation including allogenic stem-cell transplantation. 16. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. 17. Concurrent treatment with a non-permitted drug. 18. Patients suspected by the physician that he/she will not compliant to the protocol conduct. 19. Pregnant or breastfeeding patients. 20. Patient participating in another clinical trial. 21. Patient who is not willing to sign the consent form. 22. Any psychiatric condition that would prohibit the understanding or rendering of informed consent. 23. Legal incapacity or limited legal capacity patients receiving other oncology specific medication not authorized in the protocol.

Study Design


Intervention

Drug:
COMPOUND 2055269
COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
Radiation:
Radiation Therapy
Radiotherapy 25 Gy to be given on Days 1-5
Drug:
mFOLFOX
Given every 2 weeks for 6 cycles
Procedure:
Total Mesorectal Excision
Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269

Locations

Country Name City State
Jordan King Hussein Cancer Center Amman
Lebanon American University of Beirut Medical Center Beirut
Lebanon Hôtel Dieu de France Beirut

Sponsors (3)

Lead Sponsor Collaborator
Ali Shamseddine Merck KGaA, Darmstadt, Germany, Phoenix Clinical Research

Countries where clinical trial is conducted

Jordan,  Lebanon, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269 Will be done via pathologic assessment on the surgical specimen After 17 weeks (once surgery is done)
Secondary The proportion of patients who remain progression free at 3 years. 1) Progression free survival is measured by imaging and serial tumor markers during follow up visits 3 years
Secondary PD-L1 expression and T-cell infiltration changes after treatment 2) PD-L1 & T cell infiltration is measured by a pathology assessment on day 10 and after surgery At day 10 biopsy and after 17 weeks (once surgery is done)
Secondary Number of participants with treatment- related adverse events as assessed by NCI-CTCAE v4.0 Treatment- related adverse events are assessed by NCI-CTCAE v4.0 in each visit 3 years
Secondary Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire Quality of life is measured via FACT-C questionnaire in each visit. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05079438 - Dendrobium Huoshanense Suppository in Rectal Cancer Phase 3
Recruiting NCT02964468 - Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer N/A
Not yet recruiting NCT05507112 - TIME in Immunotherapy Combined With nCRT for Rectal Cancer Phase 2
Not yet recruiting NCT05998122 - Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study Phase 2
Completed NCT04324567 - Inflammation After Laparoscopic Robot-assisted Surgery for Locally Advanced Rectal Cancer
Recruiting NCT05412082 - SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer Phase 1
Recruiting NCT05980689 - Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer Phase 2
Recruiting NCT02605265 - Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 Phase 3
Terminated NCT02151019 - Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer Phase 1/Phase 2
Recruiting NCT05086627 - Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer Phase 2
Not yet recruiting NCT05076305 - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Recruiting NCT03824899 - UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer N/A
Recruiting NCT05845268 - Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer Phase 2
Completed NCT03392584 - Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
Terminated NCT04177602 - Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial Phase 1/Phase 2
Recruiting NCT05646511 - Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE) Phase 3
Terminated NCT02290574 - Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial N/A
Recruiting NCT03702985 - Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer Phase 2
Active, not recruiting NCT05877352 - Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial N/A
Not yet recruiting NCT06375434 - Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer